Abstract Gain of chromosome 1q (+ 1q) is one of the most common recurrent cytogenetic
abnormalities in multiple myeloma (MM), occurring in approximately 40% of newly …

The outcomes for the majority of patients with myeloma have improved over recent decades,
driven by treatment advances. However, there is a subset of patients considered to have …

RNA-binding proteins (RBPs) are emerging as important effectors of the cellular DNA
damage response (DDR). The RBP FUS is implicated in RNA metabolism and DNA repair …

A number of clinically validated drugs have been developed by repurposing the CUL4-
DDB1-CRBN-RBX1 (CRL4CRBN) E3 ubiquitin ligase complex with molecular glue …

To date, the choice of therapy for an individual multiple myeloma patient has been based on
clinical factors such as age and comorbidities. The widespread evolution, validation, and …

Long non-coding RNAs (lncRNAs) play important roles in carcinogenesis. However, the
effect of lncRNA on chemoresistance and RNA alternative splicing remains largely …

Codon bias has been implicated as one of the major factors contributing to mRNA stability in
several model organisms. However, the molecular mechanisms of codon bias on mRNA …

Senescence and altered differentiation potential of bone marrow stromal cells (BMSCs) lead
to age‐related bone loss. As an important posttranscriptional regulatory pathway, alternative …

Abstract circRNAs arise from back splicing events during mRNA processing, and when
deregulated can play an active role in cancer. Here we characterize a new circRNA …

The genetic etiology of premature ovarian insufficiency (POI) has been well established to
date, however, the role of long noncoding RNAs (lncRNAs) in POI is largely unknown. In this …